Australia markets closed
  • ALL ORDS

    6,865.30
    +18.00 (+0.26%)
     
  • ASX 200

    6,634.10
    +18.80 (+0.28%)
     
  • AUD/USD

    0.7436
    -0.0003 (-0.04%)
     
  • OIL

    45.87
    +0.23 (+0.50%)
     
  • GOLD

    1,836.60
    -4.50 (-0.24%)
     
  • BTC-AUD

    25,529.08
    -368.04 (-1.42%)
     
  • CMC Crypto 200

    372.02
    -7.23 (-1.91%)
     
  • AUD/EUR

    0.6121
    -0.0001 (-0.01%)
     
  • AUD/NZD

    1.0562
    +0.0051 (+0.48%)
     
  • NZX 50

    12,631.38
    -17.53 (-0.14%)
     
  • NASDAQ

    12,514.01
    +46.88 (+0.38%)
     
  • FTSE

    6,550.23
    +59.96 (+0.92%)
     
  • Dow Jones

    30,144.69
    +175.17 (+0.58%)
     
  • DAX

    13,298.96
    +46.10 (+0.35%)
     
  • Hang Seng

    26,835.92
    +107.42 (+0.40%)
     
  • NIKKEI 225

    26,751.24
    -58.13 (-0.22%)
     

Clearside Biomedical to Report Third Quarter 2020 Financial Results and Provide Corporate Update on Tuesday, November 10, 2020

Clearside Biomedical, Inc.
·1-min read

ALPHARETTA, Ga., Oct. 30, 2020 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (NASDAQ:CLSD), a biopharmaceutical company dedicated to developing and delivering treatments that restore and preserve vision for people with serious back of the eye diseases, announced today that its third quarter 2020 financial results will be reported on Tuesday, November 10, 2020 after the close of the financial markets. Management will host a webcast and conference call at 4:30 p.m. Eastern Time to discuss the results and provide a corporate update.

The live and archived webcast may be accessed on the Clearside website under the Investors section: Events and Presentations. The live call can be accessed by dialing (844) 263-8310 (domestic) or (213) 358-0959 (international) and entering conference code: 3169417.

About Clearside Biomedical

Clearside Biomedical, Inc. is a biopharmaceutical company dedicated to developing and delivering treatments that restore and preserve vision for people with serious back of the eye diseases. Clearside’s proprietary SCS Microinjector® targets the suprachoroidal space (SCS®) and offers unique access to the macula, retina and choroid where sight-threatening disease often occurs. The Company’s SCS injection platform is an inherently flexible, in-office, non-surgical procedure, intended to provide targeted delivery to the site of disease and to work with both established and new formulations of medications, as well as future therapeutic innovations such as gene therapy. For more information, please visit www.clearsidebio.com.

Investor and Media Contacts:

Jenny Kobin
Remy Bernarda
ir@clearsidebio.com
(678) 430-8206

Source: Clearside Biomedical, Inc.